Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY

v3.20.4
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Total
Balance at Dec. 31, 2018 $ 133,908 $ 17,528,947 $ (33,225,107) $ (15,562,252)
Balance (in shares) at Dec. 31, 2018 133,907,747      
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Stock-based compensation expense $ 0 680,455 0 680,455
Warrants issued in connection with convertible multi-draw credit agreement, related party 0 716,110 0 716,110
Beneficial conversion feature in connection with convertible multi-draw credit agreement - related party 0 1,584,850 0 1,584,850
Issuance of common stock net of issuance costs of $16,900 $ 8,000 1,911,372 0 1,919,372
Issuance of common stock net of issuance costs of $16,900 (in shares) 8,000,000      
Series B warrant exercises $ 187 144,188 0 144,375
Series B warrant exercises (in shares) 187,500      
Exercise of Emerald financing warrants $ 40,800 9,972,523 0 10,013,323
Exercise of Emerald financing warrants (in shares) 40,800,000      
Net loss for the year $ 0 0 1,051,825 1,051,825
Balance at Dec. 31, 2019 $ 182,895 32,538,445 (32,173,282) 548,058
Balance (in shares) at Dec. 31, 2019 182,895,247      
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Stock-based compensation expense $ 0 302,742 0 302,742
Issuance of common stock net of issuance costs of $16,900 $ 56,333 6,029,256 0 6,085,589
Issuance of common stock net of issuance costs of $16,900 (in shares) 56,333,334      
Exercise of pre-funded warrants $ 48,533 0 0 48,533
Exercise of pre-funded warrants (in shares) 48,533,334      
Series B warrant exercises $ 313 26,250 0 26,563
Series B warrant exercises (in shares) 312,500      
Net loss for the year $ 0 0 (6,560,699) (6,560,699)
Balance at Dec. 31, 2020 $ 288,074 $ 38,896,693 $ (38,733,981) $ 450,786
Balance (in shares) at Dec. 31, 2020 288,074,415